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Background: Treatment with glucocorticoids after snakebite in dogs is controversial and randomized clinical studies are
missing. The objective of this study was to investigate the effect of a single dose of prednisolone in dogs envenomated
by Vipera berus in a double-blind placebo-controlled study, after exclusion of dogs treated with antivenom. The two
treatment groups were compared regarding clinical status and clinicopathological test results. A total of 75 dogs bitten
by Vipera berus within the previous 24 hours were included. Clinical assessment, blood sampling and measurement of
the bitten body part were done at admission (Day 1), after 24 hours (Day 2) and at a re-examination (Re-exam)
after 10–28 days. Dogs were given prednisolone 1 mg/kg bodyweight (PRED) or saline (PLACEBO) subcutaneously
in a randomized, double-blind clinical trial. Dogs were examined clinically and mental status and extent of edema
were described. Furthermore, appetite, vomiting, diarrhea, cardiac arrhythmia and death were recorded. Concentrations
of C-reactive protein (CRP) and high sensitivity cardiac Troponin I (cTnI), hematology variables and Prothrombin time
(PT) were determined. Systemic inflammation was defined as present if CRP > 35 mg/l.
Results: None of the dogs died during the study period. The mental status was reduced in 60/75 (80%) of dogs
on Day 1, compared to 19/75 (25%) on Day 2. The proportion of dogs with no or only mild edema increased
significantly from Day 1 to Day 2. About one-third of the dogs developed gastrointestinal signs during the study period.
Cardiac arrhythmia was uncommon. Clinicopathological changes included increased total leucocyte count, CRP and
troponin concentration on Day 2. The cTnI concentration was increased in dogs with systemic inflammation, compared
to dogs without systemic inflammation. A single dose of prednisolone did not significantly affect any of the clinical or
clinicopathological parameters studied, except for a higher monocyte count on Day 2 in dogs that had received
prednisolone treatment.
Conclusion: The results of the present study do not support routine administration of a single dose of prednisolone
1 mg/kg subcutaneously in dogs bitten by Vipera berus.
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Vipera berus (V. berus) is the only venomous snake spe-
cies in Sweden and every year about 1500–2000 dogs re-
quire veterinary care because of snake envenomation
(Olsson P-E, Agria Pet Insurance Co, personal commu-
nication, 2012). The viper venom has proteolytic, fi-
brinolytic, anticoagulant and phospholipase A2 effects
[1,2]. Clinical findings in dogs bitten by V. berus include* Correspondence: bodil.strom-holst@slu.se
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unless otherwise stated.local edema, pain, reduced mental status and cardiac
arrhythmia [3-6]. The reported mortality ranges from 0
to 4.6% [3,4,6]. Common hematological findings in dogs
bitten by V. berus are leucocytosis and increased
hematocrit [2,3]. Minor liver injury has also been found
[4] as well as myocardial cell damage [7,8]. Biochemical
evidence of systemic inflammation has been described
and was associated with biochemical signs of myocar-
dial injury [7], but the degree of systemic inflammation
has so far not been related to clinical status.
Therapy for dogs bitten by V. berus is mainly supportive,
and includes intravenous (IV) fluids, opioid analgesics,ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment with antivenom can be recommended for dogs
with moderate to severe clinical signs and may improve
the general condition [5]. Treatment with glucocorticoids
after snakebite in both humans and dogs is common but
still controversial [4,6,9-12]. In humans bitten by V. berus,
glucocorticoid treatment is only recommended in cases of
acute allergic reactions against the venom, bronchospasm,
or serum sickness after antivenom administration [10].
The aim of the present study was to describe the ef-
fect of a single dose of prednisolone 1 mg/kg subcuta-
neously in dogs bitten by V.berus in a prospective,
double-blind placebo-controlled clinical trial. The two
treatment groups were compared regarding clinical sta-
tus and clinicopathological test results with special
focus on inflammation.Methods
Dogs
The study was done between April 2011 and September
2012 at two Swedish referral animal hospitals in central
Sweden: Evidensia Södra Djursjukhuset (Animal Hos-
pital 1) and Evidensia Specialistdjursjukhuset Ström-
sholm (Animal Hospital 2). Inclusion criteria were a
reported snake bite (observation of a snake, fang marks
or a very high suspicion of a snake bite) within the pre-
vious 24 h and presence of clinical signs typical of en-
venomation by V. berus (sudden development of local
swelling and pain in the area of the suspected bite)
within 2 h after the bite. Exclusion criteria were treat-
ment with glucocorticoids or nonsteroidal antiinflamma-
tory drugs (NSAID), pregnancy, vaccination within the
last 2 weeks or renal disease, diabetes mellitus or hyper-
adrenocorticism. Dogs treated with antivenom were ex-
cluded. Other ongoing inflammatory disease was not an
exclusion criterion but all medical records were reviewed
retrospectively with respect to reported health status.
One dog suffered from acute mastitis and was excluded
from the CRP analysis.
At Animal Hospital 1, all owners arriving with a dog
that met the inclusion criteria were asked if they
wanted to participate in the study and all dogs were re-
corded, even those not enrolled in the study. In total
141 dogs met the inclusion criteria but 90 dogs were
excluded because of treatment with glucocorticoids or
NSAID (n = 17), pregnancy (n = 2), vaccination (n = 1),
declination of the owner (n = 11), no further hospital
stay after the initial examination (n = 5), negligence
from the attending veterinarian to include the dog (n =
49) or treatment with antivenom (n = 5). Thus, in total
51 dogs were included at Animal Hospital 1 and 24
dogs at Animal Hospital 2. A total of 75 dogs were thus
included in the study.Clinical assessments
All dogs were clinically examined by the attending veter-
inary surgeon on presentation (Day 1), after 24 h ± 5 h
at Animal Hospital 1 or after 24 h ± 12 h at Animal Hos-
pital 2 (Day 2), and at a follow-up visit after 10 to 28 days
(Re-exam). At Animal Hospital 1 the results from the
clinical examination were recorded both in a study
protocol and in the medical records, whereas the infor-
mation at Animal Hospital 2 was retrieved mostly from
medical records due to incomplete data in the study
protocol. Presence of diarrhea was determined retro-
spectively from the medical records. The time elapsed
from the snake bite until the dog was clinically examined
was recorded. Measurements of the bitten body parts
were performed to assess the edema. If the dog was bit-
ten on the nose, lips or in the face, the circumference of
the middle of the muzzle was measured. If the dog was
bitten in a paw or leg, a measurement was done where
the dog was most swollen and this spot was marked with
color or by shaving the fur over the area. A pilot study
was performed at Animal Hospital 1 to test the meas-
urement procedure. Fifteen veterinarians measured the
muzzle and front paw of 2 healthy dogs (1 Labrador Re-
triever and 1 Jack Russel Terrier). The estimated accur-
acy of measurements was ± 0.5 cm (unpublished data).
The circumference on Day 1 and Day 2 were compared
to the circumference at Re-exam. At Re-exam no edema
persisted and the circumference at Re-exam was used as
a baseline to calculate the increase in percentage on the
two first examination occasions. The edema was de-
scribed as absent, mild, moderate or severe. Medical re-
cords from Day 1 until the day of Re-exam were studied,
and presence of appetite, vomiting, diarrhea cardiac
arrhythmia or death was recorded.
In 54 dogs Re-exam was done, but 21 dogs were lost
to this follow-up examination. The owners of 6 of the 21
dogs were interviewed by telephone and reported that
their dogs were recovering.
Design of the clinical trial
Each dog was given a subcutaneous (SC) injection of ei-
ther prednisolonea (PRED) 1 mg/kg bodyweight (bw) or
0.9% NaCl (PLACEBO) by a technician in a dose of
0.1 ml/kg bw, according to a premade randomization
list. The injection was given at admission, immediately
after clinical examination and blood sampling were done.
Neither the veterinary surgeon in charge nor the dog
owner was aware of whether the dog received PRED (n =
38) or PLACEBO (n = 37) treatment. Dogs were further
treated as decided by the veterinary surgeon in charge of
the patient. The management of the cases was not affected
by participation in the study, except that administration of
glucocorticoids was not permitted. All dogs were treated
with IV fluid and opioid analgesics (methadone or
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the veterinary surgeon in charge.
The main outcome variables for the clinical trial were
mental status and edema. Further, differences between
the PRED and the PLACEBO group regarding appetite,
vomiting, diarrhea, cardiac arrhythmia and death were
investigated. In addition, concentrations of CRP, high
sensitivity cardiac Troponin I (cTnI), hematology vari-
ables and Prothrombin time (PT) were compared be-
tween the groups.
Blood sampling and laboratory analyses
Blood was obtained from the cephalic or saphenous vein
and collected in nonadditive (serum) and EDTA tubes
on Day 1, 2 and at Re-exam. Serum samples were centri-
fuged 30 min after collection (5000 g, 5 min) and stored
in cryotubesb at −20°C for a maximum of 5 months.
Samples were then transferred to −80°C where they were
stored until analysis after a maximum of 24 (CRP) and
36 (cTnI) months, respectively. The complete blood
count (CBC) was determined with fresh blood using an
automated impedance hematology analyzerc [13] at Ani-
mal Hospital 1, and an automated laser-based hematology
analyzerd [14,15] at Animal Hospital 2. After analysis,
samples were centrifuged and plasma stored as for serum
until PT analysis after a maximum of 24 months. Blood
smears from Day 1 and Day 2 from dogs admitted to Ani-
mal Hospital 1 were evaluated, and a manual differential
count was performed. Differential and platelet counts
were reported only in dogs that had a manual differential
count performed (i.e. admitted to Animal Hospital 1). C-
reactive protein was measured with a previously validated
canine-specific immunoturbidimetric assaye on a fully au-
tomated chemistry/immunoassay analyzerf [16]. The limit
of quantification for this assay was 6.8 mg/l and lower re-
sults were reported as <6.8 mg/l. Systemic inflammation
was defined as CRP > 35 mg/l [17].
Cardiac Troponin I (cTnI) was analyzed with a com-
mercially available high-sensitivity immunoassayg vali-
dated for use in dogs [18]. A combined prothrombin
time (PT) reagent was used for measuring activity of co-
agulation factors II, VII and Xh . The reference range of
the PT test was < 25 s and results below 25 s were re-
ported as < 25 s.
Statistical analysis
Statistical analyses and calculations were performed
using the commercial software R 3.0.1 and in Minitab
(Minitab Inc. State College, PA, USA). Descriptive statis-
tics were done for all continuous variables and included
mean, median, and standard deviation (SD). Spearman’s
rank correlation coefficient (rs) was used to assess bivari-
ate relationship amongst variables. McNemar’s test was
used to compare the mental status and swelling on Day1 with the same findings on Day 2. The chi-square pro-
portion test was used to evaluate the differences of the
distribution of clinical parameters (mental status, appe-
tite, arrhythmia, vomiting, and diarrhea) between the
PRED and PLACEBO groups. The unequal variance t-
test was conducted to evaluate differences in WBC,
swelling, duration of hospitalization, body weight and
time elapsed from snake bite between the PRED and
PLACEBO group. The Mann–Whitney U-test was used
to evaluate differences in variables that were not nor-
mally distributed, which included CRP, hematocrit,
troponin and PT. The level of statistical significance was
set to p < 0.05.
Ethical approval
The study was approved by the Local Ethical Committee
on Animal Experiments (C31/11), and the Swedish
Board of Agriculture (31-13905/10) and was approved as
a clinical trial by the Swedish Medical Products Agency
(152:2011/3282). Written owner consent was obtained
for all dogs prior to inclusion in the study.
Results
Dogs
The 75 studied dogs represented 42 different breeds.
There were 34 males, 35 females, 3 neutered males and
3 spayed females. The median age was 3 years (IQR 1–
6) and the median weight 20.5 kg (IQR 11.8-28.0). The
median time from snake bite to arrival at the animal
hospital was 2.5 h (IQR 1.9-3.6), with a median duration
of hospitalisation of 2 days (IQR 1.9-3.6). In total 62
dogs were bitten in the head region and 13 in a limb
region.
Clinical status
On Day 1 the mental status was normal in 15 dogs,
mildly reduced in 37 dogs and moderately reduced in 22
dogs. The edema was considered to be mild in 10 dogs,
moderate in 47 dogs and severe in 10 dogs. The appetite
was not possible to describe accurately at arrival on Day
1. Cardiac arrhythmia was detected in 1 dog.
On Day 2, significantly more dogs (n = 56, p < 0.0001)
had a normal mental status compared to Day 1. The
mental status was mildly reduced in 17 dogs. Edema was
determined as absent in 3 dogs, mild in 25 dogs, moder-
ate in 29 dogs and severe in 11 dogs. Significantly more
dogs had no or only mild edema Day 2 compared to Day
1 (p = 0.0013). At least 20 dogs (Data not available from
all dogs included at Animal Hospital 2) had a reduced
appetite. Cardiac arrhythmia was detected in 1 dog (not
the same dog as that in which cardiac arrhythmia was
detected on Day 1).
Vomiting was reported in 17 dogs and diarrhea in 14
dogs during the study period. In total, gastrointestinal
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dogs. The edema had disappeared and the mental status
was normal in all dogs by the time of Re-exam. None of
the 75 dogs died during the study period.
Clinicopathological parameters
C-reactive protein (CRP)
The median CRP concentration was < 6.8 mg/l on Day 1.
Of 49 dogs that were presented at the animal hospital
within 4 h after the snake bite, all except 3 had CRP
concentration < 6.8 mg/l at the arrival, whereas the 11
dogs that arrived ≥ 4 h after the snake bite had a median
(IQR) CRP concentration of 24 (17–28) mg/l. CRP con-
centration on Day 1 was positively correlated with time
elapsed from bite to admission (rs = 0.39, p < 0.01). CRP
concentration increased to a median (IQR) concentra-
tion of 74 mg/l (41–101) on Day 2 (p < 0.001). At this
time (Day 2), the CRP concentration was positively cor-
related to degree of swelling for the 33 dogs for which
data on both variables were available (rs = 0.38, p = 0.04),
but CRP concentration did not differ between dogs with
normal and dogs with decreased mental status (p = 0.45).
Systemic inflammation was present in 39/49 (80%) of
the dogs on Day 2. At Re-exam, the CRP concentration
was < 6.8 mg/l in 42/46 (91%) dogs, and no dog had CRP
concentration > 35 mg/l (systemic inflammation).
Prothrombin time (PT) and hematology
PT was within the reference range (<25 s) on Day 1 (46
samples) and Day 2 (38 samples) for all dogs except 3
dogs on Day 1 (25.6, 30.0 and 25.5 s) and 3 dogs on Day
2 (29.4, 44.5, 25.2 s). Of these dogs, 2 had increased PT
on both Day 1 and Day 2. On Re-exam (35 samples) PT
was within reference range for all tested dogs. The me-
dian (IQR) hematocrit was 47 (42–52)% on Day 1 (69
samples), 40 (34–44.5)% on Day 2 (49 samples) and 43
(39.5-48)% on Re-exam (41 samples). The hematocrit
was significantly lower on Day 2 (p < 0.01) and Re-exam
(p = 0.01) than on Day 1. The median (IQR) WBC was
12.3 (10.5-16.4) × 109/l on Day 1 (71 samples). On Day
2, the median (IQR) WBC was significantly increased to
14.9 (12.4-18.9) × 109/l, p = 0.01) (49 samples) compared
to Day 1. At Re-exam (50 samples), the median (IQR)
WBC numbers had decreased compared to both Day 1
(p < 0.01) and Day 2 (p < 0.01), to 9.6 (8.1-11.4) × 109/l.
An inflammatory leucogram, defined as band neutro-
phils > 1.0 × 109/l, was present in 10/38 (26%) blood
smears on Day 1, and in 7/32 (22%) blood smears on
Day 2. Platelet numbers were within the reference range
for healthy dogs in all investigated samples.
Cardiac troponin I (cTnI)
The median (IQR) cTnI concentration was 0.019 (0.010-
0.058) μg/l on Day 1 (55 samples). On Day 2, theconcentration of cTnI had increased significantly to
0.043 (0.021-0.29) μg/l (p = 0.001) (49 samples) and was
at Re-exam 0.013 (0.007-0.023) μg/l (46 samples), which
was significantly lower than both on Day 1 (p = 0.008)
and on Day 2 (p < 0.001).
Dogs with systemic inflammation on Day 1 and Day 2
had a significantly (p < 0.01) higher median cTnI con-
centration (0.066 ng/ml) than dogs without systemic in-
flammation (0.021 ng/ml). CRP concentrations were
significantly correlated with troponin concentrations at
Day 2 (rs = 0.35, p = 0.02), but not on Day 1 (rs = −0.12,
p = 0.38) or at Re-exam (rs = 0.03, p = 0.8).
Clinical trial
Dogs
The two groups did not differ significantly (p > 0.05) in
the distributions of breed, age, body weight, sex or
localization of the bite (Table 1). Fifty-four of the dogs
arrived to the hospital less than 4 h after the snake bite,
whereas 15 dogs arrived between 4 and 24 h after the
bite had occurred. For 5 dogs detailed information about
time elapsed from the bite was missing.
Clinical assessments
The PRED group did not differ significantly (p > 0.05)
from the PLACEBO group on Day 1 or Day 2 regarding
mental status, extent of edema, decreased appetite, or
presence of vomiting (Table 2). The appetite was not
assessed on Day 1. Cardiac arrhythmia could be detected
by auscultation in one dog in the PRED group on Day 1,
and in one dog in the PLACEBO group on Day 2.
The proportion of dogs that developed diarrhea during
the study period did not differ significantly (p = 0.2) be-
tween the PRED (5/33, 15%) and the PLACEBO (9/32,
28%) group. Duration of hospitalization did not differ
between the two groups (median duration 2 days).
Clinicopathological variables
CRP
CRP concentration did not differ significantly between
the PRED and PLACEBO group on Day 1 (p = 0.59),
Day 2 (p = 0.41) or at Re-exam (p = 0.26) (Figure 1).
Prothrombin time (PT) and hematology
The groups did not differ significantly (p > 0.05) in PT,
hematocrit or platelet numbers on any of the sampling
occasions. The two dogs with findings of abnormal PT
concentration were both treated with prednisolone
(PRED group).
The total leucocyte counts did not differ significantly
between the groups on Day 1, Day 2 or at Re-exam (p >
0.05). Differential counts did not differ between groups,
except for dogs in the PRED group with a significantly
Table 1 Baseline characteristics of case history and





Age (mean, years) 3.5 4.5
Weight (mean, kg) 21.6 21.2
Males/females 21/17 16/21
Bitten in the head region/limb 31/7 31/6
Median time (range) elapsed
from bite (hours)
2.75 (1–24) 2.25 (0.5-11.5)
The dogs were treated with 1 mg/kg bodyweight prednisolone (PRED) or
saline (PLACEBO) subcutaneously.
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dogs in the PLACEBO group (mean 0.4 × 109/l, p < 0.01).
Cardiac troponin I (cTnI)
Concentrations of cTnI were significantly higher for
dogs in the PRED group compared to dogs in the PLA-
CEBO group on Day 1 (0.032 vs 0.015 μg/L, p = 0.04),
but not on Day 2 or at Re-exam. The increase in cTnI
concentration between Day 1 and Day 2 did not differ
significantly between the groups (p = 0.9) (Table 3).
Discussion
In the present study, clinical and clinicopathological pa-
rameters in dogs bitten by V. berus are described and
the association of markers for systemic inflammation to
clinical status investigated. In addition, to our know-
ledge, this is the first randomized double-blind and
placebo-controlled clinical trial investigating the effect of
prednisolone treatment in dogs bitten by V. berus.
No dog died during the study period, and the disease
progression was benign with a mental status returning
to normal or mildly reduced in all dogs during the first
two days after the bite. Vomiting and diarrhea wasTable 2 Clinical parameters in dogs bitten by Vipera
berus
Variable Day PRED n = 38 PLACEBO n = 37
Reduced mental status 1 33/38 (87%) 27/37 (73%)
2 10/38 (26%) 7/37 (19%)
Edema1 1 1.24 (n = 17) 1.22 (n = 18)
2 1.21 (n = 17) 1.23 (n = 20)
Mild edema 1 2/34 8/33
Mild or no edema 2 12/34 16/34
Decreased appetite 2 10/34 (29%) 10/35 (29%)
Vomiting 1 6/38 (16%) 4/37 (11%)
2 4/38 (11%) 2/37 (5.4%)
1Edema was compared to the circumference of the measured area at re-
examination after 10–28 days. The number of dogs with available data on
edema is given within brackets.
The dogs were treated with 1 mg/kg bodyweight prednisolone (PRED) or
saline (PLACEBO) subcutaneously.described in 23/75 dogs (31%). Gastrointestinal signs
have previously not been reported frequently in snake-
bitten dogs, but are the most common signs of systemic
V. berus envenomation in humans [9,10,12]. Cardiac
arrhythmia was an uncommon finding in this study (2
dogs). One reason for cardiac arrhythmia being a rare
finding could be that dogs treated with antivenom were
excluded and at the animal hospitals participating, treat-
ment with antivenom is often started when arrhythmia
is detected. Cardiac arrhythmia after snake bite with V.
berus is mainly of ventricular origin [8] and usually de-
velops within 24 h of arrival [4].
Inflammation is part of the pathogenesis after snake
envenomation [2,7]. In the current study, presence of in-
flammation was confirmed by the finding of increased
CRP concentrations in most dogs (80%), as well as a left
shift in neutrophils in about 25% of the dogs. Previous
studies have shown that CRP is a quantitative marker of
inflammation [7,19], which is in accordance with the
findings in our study of a positive correlation between
degree of edema swelling and CRP concentration. The
CRP concentration did not differ between dogs with nor-
mal or decreased mental status, which may suggest that
mental status mainly is affected by factors other than in-
flammation. An additional finding in this study was that
the CRP concentration was often within the normal ref-
erence range at admission despite the presence of swell-
ing and a markedly increased CRP concentration at the
examination 24 h later (Day 2). However, after an in-
flammatory stimulus, an increase in blood CRP concen-
tration occurs within 4–6 h, reaching the maximum
concentration after approximately 24 h [7,19]. Therefore,
a low CRP concentration in a snake bitten dog can be
expected if the dog is sampled within only a few hours
after the bite occurred.
Cardiac troponin is a biomarker for myocardial cell
damage and cTnI has been studied previously in dogs
bitten by V. berus [7,8]. In the present study, the cTnI
concentration was higher in dogs with systemic inflam-
mation than in dogs without systemic inflammation.
Concentrations of cTnI and CRP were positively corre-
lated on Day 2. These findings support the hypothesis by
Langhorn et al. [7], that systemic inflammation plays a
role in the pathogenesis of myocardial injury in dogs bit-
ten by V. berus. The finding of hemoconcentration as
found here on Day 1 has also been described in other
studies of snake bite in dogs [2], and is likely to be
caused by dehydration, third space loss of fluid or
catecholamine-induced splenic contraction.
In the clinical trial, no effect of a single dose of pred-
nisolone 1 mg/kg bw SC was detected on the main out-
come variables selected, i.e. mental status and edema.
This prednisolone dose was selected based on the
Swedish recommendations for treatment of dogs bitten
Figure 1 Concentrations of C-reactive protein (CRP) in dogs bitten by Vipera berus. Concentrations are shown as box plots. Dogs are treated
with 1 mg/kg prednisolone (PRED) or saline (PLACEBO) subcutaneously.
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immune-suppressive effect [20]. The lack of a clear
positive effect of glucocorticoid treatment on clinical
signs is in accordance with the findings in a prospective
but nonrandomized previous study of 53 dogs bitten by
V. berus given various but mostly single doses of gluco-
corticoid [4]. The effect of higher or repeated doses has
hitherto not been studied. In humans, large retrospect-
ive studies have shown that treatment with corticoste-
roids is of no benefit after envenomation by V. berus
[9,10,12] and also in children bitten by green pit vipers
(Cryptelytrops albolabris and Cryptelytrops macrops),Table 3 Median troponin concentration in dogs bitten by
Vipera berus
PRED PLACEBO
Day 1 (μg/l) 0.03 0.015*
Day 2 (μg/l) 0.056 0.035
Re-Exam 0.015 0.012
*Statistically significant difference (p < 0.05) between groups
(Mann–Whitney U-test).
Dogs were treated with 1 mg/kg prednisolone (PRED) or saline
(PLACEBO) subcutaneously.1 mg/kg of prednisolone given orally for 3 days had no
effect on edema reduction [21]. There are some con-
cerns that treatment with glucocorticoids could de-
crease the effect of antivenom [22,23]. The effect of
glucocorticoids on antivenom treatment in dogs bitten
by V. berus has not been studied.
Since the introduction of antivenom, treatment with
corticosteroids has decreased in humans, as has the inci-
dence of extensive edema [10]. Treatment with anti-
venom is the only specific treatment for snake bite [24],
and based on the results of the present study it seems
reasonable to conclude that routine use of glucocorti-
coids in dogs is not necessary, although selected cases,
e.g. with allergic reactions against the snake venom,
may benefit from glucocorticoids. In addition, treatment
with prednisolone did not affect any of the investigated
clinicopathological parameters, except for dogs in the
PRED group with a higher monocyte count on Day 2
than dogs in the PLACEBO group. This may be a coin-
cidental finding because manual counting of monocytes is
not precise [25] and the mean difference between the two
groups was only 0.5 × 109/l. It was considered less likely
that the higher monocyte count in the PRED group was
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compared to the PLACEBO group there was no increased
neutrophil count or decreased lymphocyte or eosinophil
count, which has been reported earlier after treatment
with high doses of glucocorticoids [26]. The lack of a
stress leucogram could be explained by the observation
that the leucogram is normal 24 h after a single dose of
glucocorticoid [27].
This study has limitations. The presence of fang marks
or observation of a snake was often a fact but not an ab-
solute criterion for inclusion in the study, but dogs with
untypical signs, where the veterinary surgeon in charge
had concerns regarding the true presence of a snake bite,
have not been included. The risk for the diagnosis of
snake envenomation to be incorrect is therefore small.
Most dogs were first-opinion patients and representative
of dogs bitten by V. berus in Sweden, but for practical
reasons, further treatment at the Animal Hospital was
needed for inclusion in the study. Dogs with mild and
only local signs were therefore often excluded. Eleven
out of 140 dogs at Hospital 1 were not included because
the owner declined to participate, and the degree of en-
venomation was not recorded. It can thus not be ex-
cluded that severely envenomated dogs were over-
represented among these. Still, ten of the included dogs
had a severe edema. We consider the dogs participating
in the study as representative of dogs given supportive
therapy in animal hospitals after V. berus envenomation.
Assessment of mental status, edema and other clinical
parameters is subjective, especially when no objective
criteria were set up beforehand. However our results,
based on examinations by experienced veterinary sur-
geons, should be reasonably accurate. Some blood sam-
ples were missing, especially on Day 2 and from Animal
Hospital 2, and 21 dogs were lost to follow-up. Yet, be-
cause both animal hospitals are referral centers in their
area, we believe that the animal hospitals would have
been contacted if the statuses of the dogs had worsened.
Conclusion
In 75 dogs bitten by V. berus within the previous 24 hours,
frequent initial findings were reduced mental status and
decreased appetite. Development of gastrointestinal signs
was common but all dogs recovered and no dog died dur-
ing the study period. A single dose of prednisolone 1 mg/
kg bw subcutaneously did not affect clinical or clinico-
pathological parameters. Snake bite induced systemic in-
flammation, defined as CRP > 35 mg/L, was detected in
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hNormotest, Nordic Diagnostica AB, Billdal, Sweden.
Abbreviations
CRP: C-reactive protein; cTnI: Cardiac troponin I; IV: Intravenous;
SC: subcutaneous; PLACEBO: Dogs treated with 1 mg/kg saline
subcutaneously; PRED: Dogs treated with 1 mg/kg prednisolone
subcutaneously; PT: Prothrombin time; Re-exam: Follow-up examination after
10–28 days; Bw: Body weight; V. berus: Vipera berus.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EB participated in study design, data collection at Animal Hospital 1,
interpretation of data and drafting of the manuscript. AH carried out CRP
analyses, examination of blood smears, statistical calculations of CRP
correlations, interpretation of data and drafting of the manuscript. SH
participated in study design and data collection at Animal Hospital 2. RH
participated in CRP analyses, interpretation of data and drafting of the
manuscript. BSH participated in study design, storing of blood samples,
analyses of CRP, statistical calculations, interpretation of data and drafting of
the manuscript. All authors read and approved the final manuscript.
Acknowledgments
This study was supported by grants from the Swedish Veterinary Association
and the Foundation Svensk Djursjukvård. Financial support was also given by
Evidensia Djursjukvård. The authors acknowledge all dog owners, directors
and staff at the Evidensia Animal Hospitals, Södra Djursjukhuset and
Specialistdjursjukhuset Strömsholm, for their participation.
Per Wikman, Statisticon, performed several statistical calculations.
Dr Mattias Hagman, Stockholm University, contributed with knowledge in
herpetology.
Author details
1Evidensia Södra Djursjukhuset, Månskärsvägen 13, SE-141 75 Kungens Kurva,
Sweden. 2Department of Clinical Sciences, Swedish University of Agricultural
Sciences, Box 7054, SE-750 07 Uppsala, Sweden.
Received: 30 September 2014 Accepted: 5 February 2015
References
1. Calderon L, Lomonte B, Gutierrez JM, Tarkowski A, Hanson LA. Biological
and biochemical activities of Vipera berus (European viper) venom. Toxicon.
1993;31(6):743–53.
2. Goddard A, Schoeman JP, Leisewitz AL, Nagel SS, Aroch I. Clinicopathologic
abnormalities associated with snake envenomation in domestic animals. Vet
Clin Pathol. 2011;40(3):282–92.
3. Kängström L-E. Snake bite (Vipera berus) in dogs and cats. Svensk
Veterinärtidning. 1989;41(8-9):38–46. Supplement 19.
4. Lervik JB, Lilliehook I, Frendin JH. Clinical and biochemical changes in 53
Swedish dogs bitten by the European adder–Vipera berus. Acta Vet Scand.
2010;52:26.
5. Lund HS, Kristiansen V, Eggertsdottir AV, Skancke E, Ranheim B. Adverse
reactions to equine-derived F(ab’)2 -antivenin in 54 dogs envenomated by
Vipera berus berus. J Vet Emerg Crit Care (San Antonio). 2013;23(5):532–7.
6. Sutton NM, Bates N, Campbell A. Canine adder bites in the UK: a
retrospective study of cases reported to the Veterinary Poisons Information
Service. Vet Rec. 2011;169(23):607.
7. Langhorn R, Persson F, Ablad B, Goddard A, Schoeman JP, Willesen JL, et al.
Myocardial injury in dogs with snake envenomation and its relation to
systemic inflammation. J Vet Emerg Crit Care (San Antonio). 2014;24(2):174–81.
Brandeker et al. BMC Veterinary Research  (2015) 11:44 Page 8 of 88. Pelander L, Ljungvall I, Haggstrom J. Myocardial cell damage in 24 dogs
bitten by the common European viper (Vipera berus). Vet Rec.
2010;166(22):687–90.
9. Boels D, Hamel JF, Bretaudeau Deguigne M, Harry P. European viper
envenomings: assessment of Viperfav and other symptomatic treatments.
Clin Toxicol (Phila). 2012;50(3):189–96.
10. Karlson-Stiber C, Salmonson H, Persson H. A nationwide study of Vipera
berus bites during one year-epidemiology and morbidity of 231 cases. Clin
Toxicol (Phila). 2006;44(1):25–30.
11. Ozay G, Bosnak M, Ece A, Davutoglu M, Dikici B, Gurkan F, et al. Clinical
characteristics of children with snakebite poisoning and management of
complications in the pediatric intensive care unit. Pediatr Int.
2005;47(6):669–75.
12. Persson H, Irestedt B. A study of 136 cases of adder bite treated in Swedish
hospitals during one year. Acta Med Scand. 1981;210(6):433–9.
13. Roleff S, Arndt G, Bottema B, Junker L, Grabner A, Kohn B. Clinical evaluation
of the CA530-VET hematology analyzer for use in veterinary practice. Vet
Clin Pathol. 2007;36(2):155–66.
14. Lilliehook I, Tvedten H. Validation of the Sysmex XT-2000iV hematology
system for dogs, cats, and horses. I. Erythrocytes, platelets, and total
leukocyte counts. Vet Clin Pathol. 2009;38(2):163–74.
15. Lilliehook I, Tvedten H. Validation of the Sysmex XT-2000iV hematology
system for dogs, cats, and horses. II. Differential leukocyte counts. Vet Clin
Pathol. 2009;38(2):175–82.
16. Hillström A, Hagman R, Tvedten H, Kjelgaard-Hansen M. Validation of
commercially available automated canine-specific immunoturbidimetric
method for measuring canine C-reactive protein (CRP). Vet Clin Pathol.
2014;43(2):235–43.
17. Langhorn R, Oyama MA, King LG, Machen MC, Trafny DJ, Thawley V, et al.
Prognostic importance of myocardial injury in critically ill dogs with
systemic inflammation. J Vet Intern Med. 2013;27(4):895–903.
18. Langhorn R, Willesen JL, Tarnow I, Kjelgaard-Hansen M. Evaluation of a
high-sensitivity assay for measurement of canine and feline serum cardiac
troponin I. Vet Clin Pathol. 2013;42(4):490–8.
19. Kjelgaard-Hansen M, Strom H, Mikkelsen LF, Eriksen T, Jensen AL, Luntang-
Jensen M. Canine serum C-reactive protein as a quantitative marker of the
inflammatory stimulus of aseptic elective soft tissue surgery. Vet Clin Pathol.
2013;42(3):342–5.
20. Norm for treatment of dogs bitten by Vipera berus. http://svf.se/sv/
Sallskapet/Smadjurssektionen/Normgruppen/Normer-av-medicinsk-karaktar/
Norm-om-behandling-av-ormbett-hos-hund/.
21. Nuchprayoon I, Pongpan C, Sripaiboonkij N. The role of prednisolone in
reducing limb oedema in children bitten by green pit vipers: a randomized,
controlled trial. Ann Trop Med Parasitol. 2008;102(7):643–9.
22. Segev G, Shipov A, Klement E, Harrus S, Kass P, Aroch I. Vipera palaestinae
envenomation in 327 dogs: a retrospective cohort study and analysis of risk
factors for mortality. Toxicon. 2004;43(6):691–9.
23. Armentano RA, Schaer M. Overview and controversies in the medical
management of pit viper envenomation in the dog. J Vet Emerg Crit Care
(San Antonio). 2011;21(5):461–70.
24. Lalloo DG, Theakston RD. Snake antivenoms. J Toxicol Clin Toxicol.
2003;41(3):277–90. 317–227.
25. Kjelgaard-Hansen M, Jensen AL. Is the inherent imprecision of manual
leukocyte differential counts acceptable for quantitative purposes? Vet Clin
Pathol. 2006;35(3):268–70.
26. Braun JP, Guelfi JF, Thouvenot JP, Rico AG. Haematological and biochemical
effects of a single intramuscular dose of 6 alpha-methylprednisolone acetate
in the dog. Res Vet Sci. 1981;31(2):236–8.
27. Jasper DE, Jain NC. The influence of adrenocorticotropic hormone and
prednisolone upon marrow and circulating leukocytes in the dog. Am J Vet
Res. 1965;26(113):844–50.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
